Tevogen Bio Holdings Inc. (TVGN): Nasdaq/NYSE listing notice — Semper Paratus gets Nasdaq deficiency notice for MVLS below $50M

Tevogen Bio Holdings Inc.

Nasdaq notified Semper Paratus on April 4, 2023, that its MVLS fell below $50M, violating Listing Rule 5450(b)(2)(A).
The company has 180 calendar days, until October 2, 2023, to regain compliance by closing at $50M+ for 10 consecutive business days.
If not cured by that date, Nasdaq will issue a delisting notice; the company may appeal or seek transfer to the Nasdaq Capital Market.
The deficiency notice is not an immediate delisting and has no current effect on trading of LGSTU, LGST, or LGSTW.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Tevogen Bio Holdings Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5450(b)(2)(A)

Exact text from the filing

April 4, 2023, Semper Paratus Acquisition Corporation (the “Company”) received a written notice (the “Letter”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company was not in compliance with Listing Rule 5450(b)(2)(A), requiring the Company to maintain a Market Value of Listed Securities (“MVLS”) of $50,000,000 for the continued listing of its securities on The Nasdaq Global Market. The Letter is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securi

View on SEC.gov

2 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Tevogen Bio Holdings Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-043135

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.